Does CAR-T therapy affect the brain? a study investigates
NCT ID NCT07740317
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This study follows people with relapsed or refractory multiple myeloma who are scheduled to receive BCMA CAR-T therapy, a type of cell treatment. Researchers will test memory, attention, and other thinking skills at the start and again at 1, 6, and 12 months after the infusion. The goal is to see if any cognitive changes occur over time and how common they might be.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Standardized neurocognitive testing (cognitive assessments at baseline and at 1, 6, and 12 months after CAR-T infusion)
- What this could lead to
- If this trial succeeds, it could reveal whether CAR-T therapy affects thinking and memory in myeloma patients, guiding future monitoring and support.
- What could go wrong
- This is an observational study with a small group (50 people), so results may not apply to everyone. Also, cognitive changes could be due to the disease or other treatments, not just CAR-T.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CART THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Atrium Health Levine Cancer
Charlotte, North Carolina, 28204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- MRI scans may reveal hidden clues to myeloma relapse risk
- Can a dual immunotherapy erase hidden myeloma cells?
- Can a single gene therapy turn the body into a Cancer-Fighting factory?
- Can a closer look at bone complications in multiple myeloma improve rehabilitation?
- Gene-Guided Chemo-Free strategy targets AL amyloidosis
- Simple blood test could spot hidden myeloma years early